SU 4984: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 5941540 |
| CHEMBL ID | 315546 |
| SCHEMBL ID | 141892 |
| MeSH ID | M0275620 |
| PubMed CID | 5353975 |
| SCHEMBL ID | 4624850 |
| SCHEMBL ID | 20898243 |
| MeSH ID | M0275620 |
| Synonym |
|---|
| CHEMBL315546 , |
| su-4984 |
| bdbm50065306 |
| 4-{4-[2-oxo-1,2-dihydro-indol-(3z)-ylidenemethyl]-phenyl}-piperazine-1-carbaldehyde |
| 4-[4-[(z)-(2-oxo-1h-indol-3-ylidene)methyl]phenyl]piperazine-1-carbaldehyde |
| SCHEMBL141892 |
| (z)-4-(4-((2-oxoindolin-3-ylidene)methyl)phenyl)piperazine-1-carbaldehyde |
| MS-25027 |
| HY-118203 |
| 4-(4-((2-OXOINDOLIN-3-YLIDENE)METHYL)PHENYL)PIPERAZINE-1-CARBALDEHYDE |
| CS-0065433 |
| su 4984 |
| 1-piperazinecarboxaldehyde, 4-[4-[(e)-(1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]phenyl]- |
| 3[4-(1-formylpiperazin-4-yl)benzylidenyl]-2-indolinone |
| 1-piperazinecarboxaldehyde, 4-[4-[(1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]phenyl]- (9ci) |
| 3-[4-(1-formylpiperazin-4-yl)benzylidenyl]-2-indolinone |
| 4-[4-[(e)-(2-oxo-1h-indol-3-ylidene)methyl]phenyl]piperazine-1-carbaldehyde |
| SCHEMBL4624850 |
| J-011987 |
| ZNFJBJDODKHWED-QGOAFFKASA-N |
| SCHEMBL20898243 |
| E77643 |
| AKOS040759629 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0000 | 0.5369 | 10.0000 | AID66455 |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | IC50 (µMol) | 90.2000 | 0.0001 | 0.5453 | 10.0000 | AID81574 |
| Proto-oncogene tyrosine-protein kinase receptor Ret | Homo sapiens (human) | IC50 (µMol) | 1.1000 | 0.0001 | 0.3484 | 3.5970 | AID459247 |
| Insulin-like growth factor 1 receptor | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0003 | 0.4308 | 8.0000 | AID93091 |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | IC50 (µMol) | 5.1000 | 0.0006 | 0.8007 | 8.5000 | AID161261 |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0002 | 0.9420 | 10.0000 | AID1431253; AID415654 |
| Fibroblast growth factor receptor 1 | Mus musculus (house mouse) | IC50 (µMol) | 20.0000 | 0.0430 | 6.6810 | 10.0000 | AID1431254; AID415655 |
| Vascular endothelial growth factor receptor 2 | Mus musculus (house mouse) | IC50 (µMol) | 5.1286 | 0.0015 | 0.3672 | 5.1286 | AID216622 |
| Vascular endothelial growth factor receptor 1 | Mus musculus (house mouse) | IC50 (µMol) | 1.6000 | 0.4000 | 0.9600 | 1.6000 | AID217172 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID415760 | Inhibition of EGFR phosphorylation in mouse NIH/3T3 cells at 200 uM | 1997 | Science (New York, N.Y.), May-09, Volume: 276, Issue:5314 | Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. |
| AID1173866 | Antiproliferative activity against human NCI-H1975 cells at 10 uM after 72 hrs by MTS assay | 2014 | Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24 | Synthesis and biological evaluation of novel oxindole-based RTK inhibitors as anti-cancer agents. |
| AID1173868 | Antiproliferative activity against human U251 cells at 10 uM after 72 hrs by MTS assay | 2014 | Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24 | Synthesis and biological evaluation of novel oxindole-based RTK inhibitors as anti-cancer agents. |
| AID1173874 | Antiproliferative activity against human SKBR3 cells at 10 uM after 72 hrs by MTS assay | 2014 | Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24 | Synthesis and biological evaluation of novel oxindole-based RTK inhibitors as anti-cancer agents. |
| AID415663 | Inhibition of PDGFR tyrosine phosphorylation in mouse NIH3T3 cells | 1997 | Science (New York, N.Y.), May-09, Volume: 276, Issue:5314 | Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. |
| AID1173871 | Antiproliferative activity against human HCC827 cells at 10 uM after 72 hrs by MTS assay | 2014 | Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24 | Synthesis and biological evaluation of novel oxindole-based RTK inhibitors as anti-cancer agents. |
| AID1173882 | Inhibition of recombinant FGFR1 (unknown origin) at 10 uM after 1 hr by microfluidic assay | 2014 | Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24 | Synthesis and biological evaluation of novel oxindole-based RTK inhibitors as anti-cancer agents. |
| AID415659 | Inhibition of FGFR1 in mouse NIH/3T3 cells assessed as inhibition of acidic FGF-stimulated ERK2 phosphorylation by immunoblotting | 1997 | Science (New York, N.Y.), May-09, Volume: 276, Issue:5314 | Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. |
| AID1431253 | Inhibition of FGFR1 kinase domain (unknown origin) | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | An overview of the binding models of FGFR tyrosine kinases in complex with small molecule inhibitors. |
| AID93091 | Concentration required to achieve 50% inhibition of tyrosine phosphorylation on human Insulin-like growth factor I receptor | 1998 | Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14 | Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. |
| AID217172 | Concentration required to achieve 50% inhibition of tyrosine phosphorylation on murine VEGF receptor (FLK-1 RTK). | 1998 | Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14 | Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. |
| AID81574 | Concentration required to achieve 50% inhibition of tyrosine phosphorylation on human Her-2 receptor tyrosine kinase (HER-2 RTK) | 1998 | Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14 | Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. |
| AID415757 | Inhibition of EGF-stimulated EGFR phosphorylation in mouse HER14 cells by immunoblotting | 1997 | Science (New York, N.Y.), May-09, Volume: 276, Issue:5314 | Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. |
| AID374369 | Inhibition of FGFR autophosphorylation | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Synthesis of 1-(2,6-dichlorophenyl)-3-methylene-1,3-dihydro-indol-2-one derivatives and in vitro anticancer evaluation against SW620 colon cancer cell line. |
| AID459247 | Inhibition of human recombinant His-tagged RET expressed in Sf9 insect cells | 2010 | Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4 | Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. |
| AID415826 | Inhibition of insulin receptor in mouse NIHIR cells assessed as inhibition of insulin-stimulated IRS1 phosphorylation | 1997 | Science (New York, N.Y.), May-09, Volume: 276, Issue:5314 | Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. |
| AID1431254 | Inhibition of FGF induced FGFR1 autophosphorylation in mouse NIH 3T3 cells preincubated for 5 mins followed by FGF-stimulation for 5 mins in presence of [gamma-32P]ATP by SDS-PAGE based autoradiography | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | An overview of the binding models of FGFR tyrosine kinases in complex with small molecule inhibitors. |
| AID1173872 | Antiproliferative activity against human H460 cells at 10 uM after 72 hrs by MTS assay | 2014 | Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24 | Synthesis and biological evaluation of novel oxindole-based RTK inhibitors as anti-cancer agents. |
| AID415761 | Inhibition of insulin receptor tyrosine phosphorylation in mouse NIH3T3 cells | 1997 | Science (New York, N.Y.), May-09, Volume: 276, Issue:5314 | Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. |
| AID415759 | Inhibition of EGFR in mouse HER14 cells assessed as inhibition of EGF-stimulated ERK2 activation by immunoblotting | 1997 | Science (New York, N.Y.), May-09, Volume: 276, Issue:5314 | Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. |
| AID415658 | Inhibition of FGFR1 in mouse NIH/3T3 cells assessed as inhibition of acidic FGF-stimulated ERK1 phosphorylation by immunoblotting | 1997 | Science (New York, N.Y.), May-09, Volume: 276, Issue:5314 | Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. |
| AID415662 | Inhibition of PDGFR in mouse NIH/3T3 cells assessed as PDGF-stimulated Erk2 activation by immunoblotting | 1997 | Science (New York, N.Y.), May-09, Volume: 276, Issue:5314 | Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. |
| AID216622 | Inhibitory activity against vascular endothelial growth factor receptor 2 (FLK1) | 2000 | Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16 | DoMCoSAR: a novel approach for establishing the docking mode that is consistent with the structure-activity relationship. Application to HIV-1 protease inhibitors and VEGF receptor tyrosine kinase inhibitors. |
| AID1173870 | Antiproliferative activity against human Bel7402 cells at 10 uM after 72 hrs by MTS assay | 2014 | Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24 | Synthesis and biological evaluation of novel oxindole-based RTK inhibitors as anti-cancer agents. |
| AID415655 | Inhibition of acidic FGF-stimulated FGFR1 tyrosine autophosphorylation in mouse NIH/3T3 cells by immunoblotting | 1997 | Science (New York, N.Y.), May-09, Volume: 276, Issue:5314 | Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. |
| AID66455 | Concentration required to achieve 50% inhibition of tyrosine phosphorylation on human Epidermal growth factor receptor (EGF RTK). | 1998 | Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14 | Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. |
| AID415758 | Inhibition of EGFR in mouse HER14 cells assessed as inhibition of EGF-stimulated Shc phosphorylation by immunoblotting | 1997 | Science (New York, N.Y.), May-09, Volume: 276, Issue:5314 | Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. |
| AID1173869 | Antiproliferative activity against human SGC7901 cells at 10 uM after 72 hrs by MTS assay | 2014 | Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24 | Synthesis and biological evaluation of novel oxindole-based RTK inhibitors as anti-cancer agents. |
| AID415656 | Growth inhibition of mouse NIH/3T3 cells assessed as inhibition of acidic FGF-stimulated [3H]thymidine incorporation | 1997 | Science (New York, N.Y.), May-09, Volume: 276, Issue:5314 | Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. |
| AID415660 | Inhibition of PDGFR in mouse NIH/3T3 cells assessed as inhibition of PDGF-stimulated tyrosine autophosphorylation by immunoblotting | 1997 | Science (New York, N.Y.), May-09, Volume: 276, Issue:5314 | Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. |
| AID415657 | Inhibition of FGFR1 in mouse NIH/3T3 cells assessed as inhibition of aFGF-stimulated pp90 phosphoprotein phosphorylation by immunoblotting | 1997 | Science (New York, N.Y.), May-09, Volume: 276, Issue:5314 | Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. |
| AID415654 | Inhibition of FGFR1K autophosphorylation activity assessed as [32P] incorporation | 1997 | Science (New York, N.Y.), May-09, Volume: 276, Issue:5314 | Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. |
| AID161261 | Test concentration required to achieve 50% inhibition of tyrosine phosphorylation on human Platelet-derived growth factor receptor beta (PDGF RTK). | 1998 | Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14 | Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. |
| AID415756 | Inhibition of insulin-stimulated insulin receptor beta subunit autophosphorylation in mouse NIHIR cells | 1997 | Science (New York, N.Y.), May-09, Volume: 276, Issue:5314 | Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. |
| AID1173873 | Antiproliferative activity against human PM8910 cells at 10 uM after 72 hrs by MTS assay | 2014 | Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24 | Synthesis and biological evaluation of novel oxindole-based RTK inhibitors as anti-cancer agents. |
| AID415661 | Inhibition of PDGFR in mouse NIH/3T3 cells assessed as inhibition of PDGF-stimulated phospholipase C gamma phosphorylation by immunoblotting | 1997 | Science (New York, N.Y.), May-09, Volume: 276, Issue:5314 | Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. |
| AID1173867 | Antiproliferative activity against human A549 cells at 10 uM after 72 hrs by MTS assay | 2014 | Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24 | Synthesis and biological evaluation of novel oxindole-based RTK inhibitors as anti-cancer agents. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (14.29%) | 6.00% |
| Reviews | 2 (33.33%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| Other | 4 (66.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||